PTC Therapeutics market cap is $4.7 b, and annual revenue was $306.98 m in FY 2019

PTC Therapeutics Net income (Q3, 2020)-69.7 M

PTC Therapeutics EBIT (Q3, 2020)-55.1 M

PTC Therapeutics Cash, 30-Sept-2020434 M

PTC Therapeutics EV4.7 B

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|

## Revenue | 34.7m | 25.2m | 36.8m | 82.7m | 194.4m | 264.7m | 307.0m |

| (27%) | 46% | 125% | ||||

## Cost of goods sold | 4.6m | 12.7m | 12.1m | ||||

## Gross profit | 189.8m | 252.1m | 294.8m | ||||

| 98% | 95% | 96% | ||||

## R&D expense | 54.9m | 79.8m | 121.8m | 117.6m | 117.5m | 172.0m | 257.5m |

## General and administrative expense | 25.2m | 44.8m | 82.1m | 97.1m | 121.3m | 153.5m | 202.5m |

## Operating expense total | 80.1m | 124.7m | 203.9m | 214.8m | 254.1m | 367.7m | 536.0m |

## Depreciation and amortization | 15.4m | 22.9m | |||||

## EBIT | (45.4m) | (99.4m) | (167.1m) | (132.1m) | (64.3m) | (115.7m) | (241.2m) |

| (131%) | (394%) | (455%) | (160%) | (33%) | (44%) | (79%) |

## Interest expense | 6.1m | 1.2m | 2.4m | 8.3m | 12.1m | 12.6m | 12.5m |

## Pre tax profit | (51.6m) | (98.4m) | (170.0m) | (141.5m) | (77.7m) | (128.1m) | (239.9m) |

## Income tax expense | (4.7m) | 485.0k | 569.0k | 1.3m | (29.0k) | 11.7m | |

## Net Income | (51.6m) | (93.8m) | (170.4m) | (142.1m) | (79.0m) | (128.1m) | (251.6m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|

## Net Income | (51.6m) | (93.8m) | (170.4m) | (142.1m) | (79.0m) | (128.1m) | (251.6m) |

## Depreciation and Amortization | 2.4m | 2.2m | 2.9m | 3.3m | 17.7m | 26.1m | 32.2m |

## Accounts Receivable | 56.1k | (3.5m) | (6.9m) | (14.8m) | (12.2m) | (29.6m) | 11.5m |

## Inventories | (6.5m) | (5.8m) | (3.5m) | ||||

## Accounts Payable | 5.2m | 16.9m | 17.0m | 4.3m | 24.0m | 43.9m | 26.8m |

## Cash From Operating Activities | (46.9m) | (57.3m) | (124.3m) | (103.6m) | (10.1m) | (27.6m) | (98.6m) |

## Purchases of PP&E | (845.7k) | (4.7m) | (2.7m) | (1.8m) | (3.1m) | (7.1m) | (13.8m) |

## Cash From Investing Activities | (127.8m) | (145.2m) | (20.8m) | 104.5m | 13.1m | (42.6m) | (387.2m) |

## Long-term Borrowings | (5.0m) | (49.0k) | |||||

## Cash From Financing Activities | 187.4m | 237.1m | 154.1m | 968.0k | 44.2m | 131.6m | 613.2m |

## Net Change in Cash | 12.7m | 34.3m | 8.3m | 299.0k | 53.5m | 57.7m | 126.0m |

## Interest Paid | 367.1k | 1.0k | 4.5m | 6.3m | 7.8m | 7.7m | |

## Income Taxes Paid | 2.1k | 111.0k | 943.0k | 1.1m | 1.6m | 2.1m |

USD | Q2, 2013 |
---|---|

## Financial Leverage | 1.1 x |